531 related articles for article (PubMed ID: 20594615)
1. Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification.
Davatzikos C; Bhatt P; Shaw LM; Batmanghelich KN; Trojanowski JQ
Neurobiol Aging; 2011 Dec; 32(12):2322.e19-27. PubMed ID: 20594615
[TBL] [Abstract][Full Text] [Related]
2. Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.
Da X; Toledo JB; Zee J; Wolk DA; Xie SX; Ou Y; Shacklett A; Parmpi P; Shaw L; Trojanowski JQ; Davatzikos C;
Neuroimage Clin; 2014; 4():164-73. PubMed ID: 24371799
[TBL] [Abstract][Full Text] [Related]
3. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
[TBL] [Abstract][Full Text] [Related]
4. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A
Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
[TBL] [Abstract][Full Text] [Related]
6. Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: results from ADNI.
Misra C; Fan Y; Davatzikos C
Neuroimage; 2009 Feb; 44(4):1415-22. PubMed ID: 19027862
[TBL] [Abstract][Full Text] [Related]
7. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
8. CSF and brain structural imaging markers of the Alzheimer's pathological cascade.
Yang X; Tan MZ; Qiu A
PLoS One; 2012; 7(12):e47406. PubMed ID: 23284610
[TBL] [Abstract][Full Text] [Related]
9. Identification of conversion from mild cognitive impairment to Alzheimer's disease using multivariate predictors.
Cui Y; Liu B; Luo S; Zhen X; Fan M; Liu T; Zhu W; Park M; Jiang T; Jin JS;
PLoS One; 2011; 6(7):e21896. PubMed ID: 21814561
[TBL] [Abstract][Full Text] [Related]
10. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
[TBL] [Abstract][Full Text] [Related]
11. Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition.
Leow AD; Yanovsky I; Parikshak N; Hua X; Lee S; Toga AW; Jack CR; Bernstein MA; Britson PJ; Gunter JL; Ward CP; Borowski B; Shaw LM; Trojanowski JQ; Fleisher AS; Harvey D; Kornak J; Schuff N; Alexander GE; Weiner MW; Thompson PM;
Neuroimage; 2009 Apr; 45(3):645-55. PubMed ID: 19280686
[TBL] [Abstract][Full Text] [Related]
12. Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project.
van Maurik IS; Zwan MD; Tijms BM; Bouwman FH; Teunissen CE; Scheltens P; Wattjes MP; Barkhof F; Berkhof J; van der Flier WM;
JAMA Neurol; 2017 Dec; 74(12):1481-1491. PubMed ID: 29049480
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
[TBL] [Abstract][Full Text] [Related]
14. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change.
Vemuri P; Wiste HJ; Weigand SD; Shaw LM; Trojanowski JQ; Weiner MW; Knopman DS; Petersen RC; Jack CR;
Neurology; 2009 Jul; 73(4):294-301. PubMed ID: 19636049
[TBL] [Abstract][Full Text] [Related]
15. Erlangen Score Predicts Cognitive and Neuroimaging Progression in Mild Cognitive Impairment Stage of Alzheimer's Disease.
Skillbäck T; Kornhuber J; Blennow K; Zetterberg H; Lewczuk P;
J Alzheimers Dis; 2019; 69(2):551-559. PubMed ID: 31104027
[TBL] [Abstract][Full Text] [Related]
16. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression.
Zetterberg H; Skillbäck T; Mattsson N; Trojanowski JQ; Portelius E; Shaw LM; Weiner MW; Blennow K;
JAMA Neurol; 2016 Jan; 73(1):60-7. PubMed ID: 26524180
[TBL] [Abstract][Full Text] [Related]
17. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
[TBL] [Abstract][Full Text] [Related]
18. White matter signal abnormality quality differentiates mild cognitive impairment that converts to Alzheimer's disease from nonconverters.
Lindemer ER; Salat DH; Smith EE; Nguyen K; Fischl B; Greve DN;
Neurobiol Aging; 2015 Sep; 36(9):2447-57. PubMed ID: 26095760
[TBL] [Abstract][Full Text] [Related]
19. Spatial correlation maps of the hippocampus with cerebrospinal fluid biomarkers and cognition in Alzheimer's disease: A longitudinal study.
Liu G; Liu C; Qiu A;
Hum Brain Mapp; 2021 Jun; 42(9):2931-2940. PubMed ID: 33739550
[TBL] [Abstract][Full Text] [Related]
20. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]